#United States #Liquid Biopsy #cancer detection #VolitionRx #Henderson, Nevada

VolitionRx's Revolutionary Liquid Biopsy Technology

In an unprecedented advancement for the field of cancer detection, VolitionRx Limited (NYSE AMERICAN: VNRX), a globally recognized epigenetics company, has successfully demonstrated a novel method for isolating and analyzing tumor-derived DNA from blood samples with a purity exceeding 99%. This breakthrough could herald a new era in liquid biopsy technology, providing a powerful tool for early cancer detection and monitoring.

Addressing a Significant Challenge in Liquid Biopsy

The primary challenge that liquid biopsy technologies face is the overwhelming presence of DNA from healthy cells in blood samples, which makes isolating cancer-derived DNA extremely difficult. Traditional methods have struggled to effectively separate these cancer signals from the noise of healthy DNA, often leading to inaccurate results.

However, Volition has addressed this issue with its innovative Capture-Seq™ technology. By employing a novel two-step method, the company has engineered a way to physically enrich the sample, followed by a bioinformatic process that effectively removes virtually all non-tumor DNA sequences. This method allows for the generation of ultra-pure circulating tumor-derived DNA (ctDNA) data sets, providing a reliable basis for cancer diagnostics.

Dr. Jake Micallef, Volition's Chief Scientific Officer, explained the significance of this discovery: “Distinguishing cancer-derived plasma DNA from healthy DNA when the two are intermixed has been a long-standing issue. Our findings indicate that, in healthy plasma, there is virtually no CTCF-bound DNA, while in the plasma of cancer patients, we find it almost exclusively derived from cancer cells.” His remarks highlight the potential of this technology to revolutionize cancer detection.

Promising Early Validation Results

Early validation studies of the Capture-Seq™ technology have yielded promising results. In a blind study involving two independent cohorts, Volition achieved an impressive detection rate of 49 out of 49 cancer cases, including early stage cancers. In the second cohort, 13 out of 14 later-stage cancers were detected, all without any false positives. Such high sensitivity and specificity could drastically improve clinical outcomes by allowing earlier intervention for cancer patients.

Dr. Andrew Retter, Volition's Medical Consultant, expressed high hopes for the future of this technology, suggesting that if these findings are validated in larger cohorts, Capture-Seq™ could significantly enhance cancer detection methods, particularly when used alongside existing assays like the Nu.Q® test for lung cancer.

Commercial Opportunities and Future Developments

As Volition looks to the future, it sees considerable commercial potential in its breakthrough technology. The company estimates that the total addressable market for multi-cancer early detection could reach approximately $23 billion annually, with an additional $13 billion for Minimal Residual Disease detection. In response to the excitement surrounding Capture-Seq™, Volition is currently in discussions with major diagnostic companies to expedite the technology's commercialization.

The updated manuscript detailing these findings is expected to be published on Research Square shortly, indicating an eagerness within the scientific community to see this work validated and applied in clinical settings.

Conclusion

The advances by VolitionRx represent a significant leap forward in the realm of cancer diagnostics. As research continues and partnerships develop, this innovative method of liquid biopsy could transform how clinicians detect and manage cancer, ultimately leading to earlier detection, more effective treatments, and better patient outcomes. The potential to revolutionize cancer diagnostics through enhanced detection not only has implications for human health but could also extend to veterinary applications, contributing to a broader spectrum of disease management.